Real world evidence
Impact and safety of using Bexsero in the real world across settings and target populations.2,3
Internet Explorer is no longer supported.
To provide you with the best possible experience, please switch to a supported browser e.g.
has been added to your basket
Bexsero is indicated for active immunisation of individuals from 2 months of age and older against invasive meningococcal disease caused by Neisseria meningitidis group B.1
2 of 3 parents are unaware that there is a separate vaccine against meningitis B.
Some parents believe that their child may have already been protected from meningitis B with just a meningococcal conjugate (MenACWY) vaccine.4,a
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline 0800 221 441
January 2022 | PM-GB-BEX-WCNT-200001 (V2.0)